Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether neurocognitive impairments experienced by
patients with chronic hepatitis C virus (HCV) infection can be reversed by treating HCV, with
a new combination of direct acting antiviral drugs (daclatasvir (DCV), asunaprevir (ASV) and
beclabuvir (BCV)). The study will assess the effect of HCV on the central nervous system
(CNS) by assessing neurocognitive function and brain injury prior to treatment, and comparing
it to the end of treatment, and 4, 12 and 24 weeks after treatment.